ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
vrs37
|
15 |
5.2K |
2 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.2K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
vrs37
|
15 |
5.2K |
2 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.2K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
IONIC
|
|
vrs37
|
14 |
4.7K |
1 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
14
|
4.7K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
A message to trolls
|
|
vrs37
|
12 |
3.8K |
6 |
03/09/21 |
03/09/21 |
ASX - By Stock
|
12
|
3.8K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Wonder Drug
|
|
vrs37
|
29 |
7.6K |
6 |
24/08/21 |
24/08/21 |
ASX - By Stock
|
29
|
7.6K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Wonder Drug
|
|
vrs37
|
29 |
7.6K |
5 |
24/08/21 |
24/08/21 |
ASX - By Stock
|
29
|
7.6K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
vrs37
|
49 |
14K |
2 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
49
|
14K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
vrs37
|
49 |
14K |
3 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
49
|
14K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
vrs37
|
23 |
8.3K |
0 |
22/08/21 |
22/08/21 |
ASX - By Stock
|
23
|
8.3K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
vrs37
|
23 |
8.3K |
1 |
22/08/21 |
22/08/21 |
ASX - By Stock
|
23
|
8.3K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
vrs37
|
71 |
23K |
4 |
20/08/21 |
20/08/21 |
ASX - By Stock
|
71
|
23K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
vrs37
|
23 |
8.3K |
5 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
23
|
8.3K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
|
|
vrs37
|
28 |
9.5K |
2 |
13/08/21 |
13/08/21 |
ASX - By Stock
|
28
|
9.5K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.6K |
2 |
10/08/21 |
10/08/21 |
ASX - By Stock
|
24
|
6.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.6K |
2 |
10/08/21 |
10/08/21 |
ASX - By Stock
|
24
|
6.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.6K |
2 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
24
|
6.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.6K |
4 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
24
|
6.6K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
|
|
vrs37
|
28 |
9.5K |
4 |
05/08/21 |
05/08/21 |
ASX - By Stock
|
28
|
9.5K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Otto Buttula appointed to the Board of OncoSil
|
|
vrs37
|
20 |
13K |
0 |
23/07/21 |
23/07/21 |
ASX - By Stock
|
20
|
13K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Otto Buttula appointed to the Board of OncoSil
|
|
vrs37
|
20 |
13K |
2 |
22/07/21 |
22/07/21 |
ASX - By Stock
|
20
|
13K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Otto Buttula appointed to the Board of OncoSil
|
|
vrs37
|
20 |
13K |
1 |
20/07/21 |
20/07/21 |
ASX - By Stock
|
20
|
13K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Any progress in marketing in UK?
|
|
vrs37
|
12 |
7.1K |
3 |
20/06/21 |
20/06/21 |
ASX - By Stock
|
12
|
7.1K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Any progress in marketing in UK?
|
|
vrs37
|
12 |
7.1K |
1 |
20/06/21 |
20/06/21 |
ASX - By Stock
|
12
|
7.1K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Novartis Vision trial result
|
|
vrs37
|
18 |
6.0K |
3 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
18
|
6.0K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Novartis Vision trial result
|
|
vrs37
|
18 |
6.0K |
4 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
18
|
6.0K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil TGA regulatory update
|
|
vrs37
|
39 |
25K |
9 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
39
|
25K
|
9
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil TGA regulatory update
|
|
vrs37
|
39 |
25K |
2 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
39
|
25K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Lu-PSMA data
|
|
vrs37
|
6 |
1.9K |
3 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
6
|
1.9K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
4 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
41
|
13K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
4 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
41
|
13K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
3 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
6 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
7 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
3 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
6 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
5 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
5 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4C - quarterly
|
|
vrs37
|
6 |
3.6K |
0 |
02/05/21 |
02/05/21 |
ASX - By Stock
|
6
|
3.6K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Publications Positive Review of Veyonda in Chemotherapy
|
|
vrs37
|
9 |
3.1K |
5 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
9
|
3.1K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4C - quarterly
|
|
vrs37
|
6 |
3.6K |
2 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
6
|
3.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
vrs37
|
15 |
3.7K |
2 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
vrs37
|
15 |
3.7K |
2 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
vrs37
|
15 |
3.7K |
2 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: $1.4M R&D Tax Rebate
|
|
vrs37
|
52 |
15K |
6 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
52
|
15K
|
6
|
|
ASX - By Stock
|
NOX |
A note from GK
|
|
vrs37
|
7 |
3.0K |
3 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
7
|
3.0K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
vrs37
|
42 |
10K |
2 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
42
|
10K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
vrs37
|
42 |
10K |
2 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
42
|
10K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
vrs37
|
42 |
10K |
2 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
42
|
10K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
vrs37
|
42 |
10K |
4 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
42
|
10K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
vrs37
|
42 |
10K |
3 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
42
|
10K
|
3
|
|